Impairment of β2 -adrenoceptor agonist relaxation by cytokines is prevented by concomitant glucocorticoid treatment for formoterol but not for salmeterol in mouse trachea Source: Eur Respir J 2007; 30: Suppl. 51, 714s Year: 2007
Differences in efficacy between formoterol and salmeterol in relaxation of the mouse trachea are accentuated by inflammatory cytokines Source: Eur Respir J 2005; 26: Suppl. 49, 370s Year: 2005
Formoterol but not salmeterol enhances cytokine release Source: Eur Respir J 2002; 20: Suppl. 38, 619s Year: 2002
Effects of fluticasone and salmeterol on cytokine-induced airway smooth muscle IP10 release Source: Eur Respir J 2005; 26: Suppl. 49, 712s Year: 2005
Formoterol is more effective than salmeterol in suppressing neutrophil reactivity Source: ERJ Open Res 2015 Year: 2015
The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC) Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Source: Eur Respir J 2002; 19: 865-871 Year: 2002
Allergen-induced airway decorin production is inhibited by budesonide and formoterol in a mouse model of asthma Source: Eur Respir J 2004; 24: Suppl. 48, 690s Year: 2004
Fluticasone does not add to the salmeterol effect on pig-dust induced inflammation in the lower airways Source: Eur Respir J 2006; 28: Suppl. 50, 433s Year: 2006
Effect of montelukast or salmeterol added to inhaled fluticasone on response to albuterol in children with exercise-induced bronchoconstriction Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Combined treatment with fluticasone plus salmeterol protects against allergen-induced asthmatic responses better than each drug alone Source: Eur Respir J 2001; 18: Suppl. 33, 349s Year: 2001
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Formoterol is more potent and more effective than salmeterol in the inhibition of oxidative burst in human eosinophils Source: Eur Respir J 2001; 18: Suppl. 33, 49s Year: 2001
Synergistic inhibition of oxidative burst in human eosinophils by combination treatment with formoterol and budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Suppressive effects of formoterol and salmeterol on eotaxin-1 in bronchial epithelial cells Source: Annual Congress 2008 - Novel therapeutic approaches and immunological mechanisms in airway cell pathobiology Year: 2008
Effect of fluticasone and formoterol combination therapy on airway remodeling Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Attenuation of exercise-induced bronchoconstriction with montelukast or salmeterol added to inhaled fluticasone in children Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Rapid inhibitory effects of budesonide and formoterol on bradykinin-induced Ca2+ mobilization in human lung fibroblasts Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Anti-inflammatory effect of beclomethasone dipropionate and formoterol on TNF-α-induced human endothelial cell activation Source: Annual Congress 2011 - Lung cell biology Year: 2011